GSK plc (GLAXF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

GSK plc (GLAXF) Healthcare & Pipeline Overview

GSK plc, a prominent player in the healthcare sector, specializes in pharmaceuticals, vaccines, and consumer health products, leveraging a robust portfolio across various therapeutic areas to address global health challenges.

What Is the Investment Thesis for GLAXF?

GSK plc's investment thesis is built on its robust market position, diverse product portfolio, and strategic collaborations. With a market capitalization of $102B and a P/E ratio of 13.7, GSK demonstrates strong financial health, supported by a profit margin of 17.8% and a gross margin of 72.7%. The company's ongoing focus on research and development, particularly in high-growth therapeutic areas such as oncology and immunology, presents significant growth catalysts. GSK's commitment to innovation is further exemplified by its collaboration agreements with leading biotech firms, which are expected to enhance its product pipeline and market reach. Additionally, the company's dividend yield of 3.38% provides a steady income stream for investors. However, potential risks include regulatory challenges and competition from generic drugs. Overall, GSK's strategic initiatives and strong financial metrics position it favorably for future growth.

Based on FMP financials and quantitative analysis

GLAXF Key Highlights

Market capitalization of $102B, indicating a significant presence in the healthcare sector.

• P/E ratio of 13.7, reflecting strong earnings relative to its share price.
• Profit margin of 17.8%, showcasing effective cost management and operational efficiency.
• Gross margin of 72.7%, significantly above the industry average, indicating strong product pricing power.
• Dividend yield of 3.38%, providing a reliable income stream for investors.

Who Are GLAXF's Competitors?

GLAXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GLAXF's Key Strengths?

Diverse product portfolio across pharmaceuticals, vaccines, and consumer healthcare.

• Strong financial metrics, including high gross and profit margins.
• Established global presence with a significant market share.
• Robust R&D pipeline with innovative therapies in development.

What Are GLAXF's Weaknesses?

Exposure to regulatory risks and compliance challenges.

• Dependence on key products for a substantial portion of revenue.
• Potential delays in drug approvals impacting market entry.
• Challenges in managing a large workforce across multiple regions.

What Could Drive GLAXF Stock Higher?

GLAXF catalyst: GSK's anticipated launch of new oncology therapies expected in late 2026, which could significantly enhance revenue streams.

• Continuous development of vaccines in response to emerging infectious diseases, positioning GSK as a leader in public health.
• Strategic partnerships with biotech firms aimed at accelerating drug development timelines and expanding product offerings.
• Investment in R&D initiatives focused on personalized medicine, which may lead to innovative therapies and improved patient outcomes.
• Expansion into emerging markets, particularly in Asia-Pacific, projected to drive sales growth over the next five years.

What Are the Key Risks for GLAXF?

Regulatory challenges that could delay product approvals and market entry.

• Intense competition from generic drugs and biosimilars impacting market share.
• Economic downturns affecting healthcare spending and budget allocations.
• Supply chain disruptions that may impact product availability and distribution.

What Are the Growth Opportunities for GLAXF?

• The company's innovative therapies and strategic partnerships with biotech firms position it to capitalize on this expanding market, particularly in immuno-oncology.
• Growth opportunity 2: The global vaccines market is projected to grow at a CAGR of 7% through 2027, driven by increasing vaccination rates and emerging infectious diseases. GSK's robust vaccine portfolio, including its collaboration with Vir Biotechnology, positions it to capture a larger share of this lucrative market.
• The company's diverse product offerings in wellness and oral health, combined with strategic marketing initiatives, will enhance its market penetration.
• Growth opportunity 4: Expansion into emerging markets presents a significant opportunity for GSK, particularly in Asia-Pacific and Latin America. With rising healthcare expenditures and increasing access to medications, GSK can leverage its established brand and product portfolio to drive sales growth in these regions.
• Growth opportunity 5: The rise of personalized medicine is transforming the pharmaceutical landscape, and GSK's collaborations with companies like 23andMe position it to lead in this area. By integrating genetic insights into drug development, GSK can create tailored therapies that meet specific patient needs, enhancing treatment outcomes.

What Are GLAXF's Competitive Advantages?

• Strong brand recognition and reputation in the healthcare industry.
• Diverse product portfolio across multiple therapeutic areas reducing dependency on single products.
• Robust R&D capabilities leading to innovative therapies and competitive advantage.
• Established partnerships with leading biotech firms enhancing product development.
• Significant market share in vaccines and consumer healthcare segments.

What Does GLAXF Do?

GSK plc, headquartered in Brentford, United Kingdom, has a rich history dating back to its founding in 1715. Originally known as GlaxoSmithKline plc, the company rebranded to GSK plc in May 2022 to reflect its commitment to innovation in healthcare. GSK engages in the creation, discovery, development, manufacture, and marketing of a diverse range of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. The company operates through four primary segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. GSK's pharmaceutical offerings encompass a wide array of therapeutic areas, including respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular, urogenital, metabolic, anti-bacterial, and dermatology. In addition, GSK provides consumer healthcare products that cater to wellness, oral health, nutrition, and skin health needs. These products come in various forms, such as nasal sprays, tablets, syrups, lozenges, and topical creams. With a strong global presence, GSK markets its products in the United Kingdom, the United States, and internationally. The company has established collaboration agreements with notable partners, including 23andMe, Novartis, and Sanofi SA, enhancing its research capabilities and product offerings. GSK's commitment to innovation and strategic partnerships positions it as a formidable player in the healthcare industry, with a focus on improving patient outcomes and advancing global health.

What Products and Services Does GLAXF Offer?

• Develop and manufacture pharmaceutical products across various therapeutic areas.
• Produce vaccines to combat infectious diseases and improve public health.
• Offer over-the-counter medicines for everyday health needs.
• Provide health-related consumer products in wellness, oral health, and nutrition.
• Engage in research and development to innovate new therapies and treatments.
• Collaborate with biotech firms to enhance product offerings and R&D capabilities.

How Does GLAXF Make Money?

• Generate revenue through the sale of prescription medications and vaccines.
• Offer consumer healthcare products that cater to everyday health and wellness.
• Engage in strategic partnerships to enhance research capabilities and product development.
• Invest in R&D to innovate and bring new therapies to market.
• Leverage a global distribution network to reach diverse markets and customer segments.

What Industry Does GLAXF Operate In?

The drug manufacturing industry is experiencing robust growth, driven by increasing healthcare demands and advancements in biotechnology. GSK plc is well-positioned within this landscape, leveraging its diverse portfolio and innovative capabilities to capture market share. The competitive landscape includes major players such as Sanofi, Merck KGaA, and CSL Limited, all of which are vying for leadership in various therapeutic areas. GSK's strategic partnerships and focus on R&D further enhance its competitive positioning, enabling it to address evolving healthcare needs effectively.

Who Are GLAXF's Key Customers?

• Healthcare providers and hospitals seeking effective treatments and therapies.
• Patients requiring prescription medications and vaccines.
• Retailers and pharmacies distributing consumer healthcare products.
• Government agencies and NGOs focused on public health initiatives.
• Research institutions collaborating on drug development and clinical trials.

Wall Street analysts project GSK plc revenue of about $34.13B for fiscal 2026, with EPS near $1.80. The estimate reflects 17 contributing analysts.

GSK plc has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 1147.1% above estimates on average.

GSK plc's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.13 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for GSK plc stands at 35.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.3%, showing how much profit it generates from its asset base. GLAXF trades at a trailing price-to-earnings ratio of 13.66, below the Healthcare sector average of ~23x. Its free cash flow yield is 6.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.79 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 7.3%, the inverse of the P/E and a quick read on earnings relative to price.

GSK plc (GLAXF) Valuation Context

Valued at $102B, GLAXF is classified as a large-cap stock. Relative to its peer group, GLAXF's quantitative score of 58/100 is roughly in line with the peer average of 48/100.

GLAXF Revenue & Earnings Trend

In Q2 2026, GLAXF generated $8.41B in top-line revenue, marking a sequential increase of 10.2%. The company recorded net income of $435.0M, with diluted EPS of $0.10. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, GLAXF averaged $0.27 in diluted EPS.

Company Profile

GSK plc operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Luke Victor Miels. GLAXF has traded publicly since 2010.

GLAXF Financials

GLAXF Latest News

GLAXF Analyst Consensus

GLAXF MoonshotScore

GLAXF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources